Lynx1 Capital Management LP Travere Therapeutics, Inc. Transaction History

Lynx1 Capital Management LP

  • $279 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$20.94 - $30.01 $8.62 Million - $12.4 Million
-411,680 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$23.61 - $30.6 $7.68 Million - $9.96 Million
-325,381 Reduced 44.15%
411,680 $10.6 Million
Q4 2021

Feb 14, 2022
BUY
$24.34 - $31.17 $17.9 Million - $23 Million
737,061 New
737,061 $22.9 Million

Others Institutions Holding TVTX

# of Institutions
193
Shares Held
84.6M
Call Options Held
776K
Put Options Held
900K
View Full List

About Travere Therapeutics, Inc.

TVTX Quotes by TradingView
  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.1B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email